Research at Providence Cancer Center shows a novel combination treatment could offer new hope for patients with advanced melanoma.
In a study of 12 clinical trial patients with metastatic melanoma, Providence Cancer Center researchers took a unique approach attacking the aggressive and deadly disease on two fronts: radiation and an immunotherapy treatment.
Marka Crittenden, M.D., Ph.D., Brendan Curti, M.D., and Steven Seung, M.D., Ph.D., all part of the Earle A. Chiles Research Institute at Providence Cancer Center, developed a clinical research trial using high-dose stereotactic body radiotherapy, or SBRT, with an immunotherapy treatment called interleukin 2, or IL-2. View the video to see how the process works.
Enter your ZIP to see local news and info